Addition of carbon as methanol or ammonium carbonate to the aqueous analyte solutions in combination with increased plasma power input enhanced the inductively coupled plasma mass spectrometry (ICP-MS) signal intensities of arsenic and selenium. In the presence of the optimum 3% v/v methanol concentration the signal intensities achieved were about 4500–5000 counts s^–1 per ng ml^–1 of arsenic and about 700–1100 counts s^–1 per ng ml^–1 of selenium (⁸²Se), corresponding to enhancement factors of 3.5–4.5 compared with aqueous solution for the two elements. Differences in sensitivity (calculated on the basis of analyte atom) were observed between the individual arsenic species and between the selenium species in aqueous as well as in carbon-added solutions. The presence of 3% v/v methanol in the analyte solutions doubled the level of the background signal for arsenic and selenium, but its fluctuation (noise) was not increased. Therefore, the observed increase in analyte sensitivity led to a similar increase in signal-to-noise ratio. The addition of carbon as ammonium carbonate enhanced the arsenic signal by a similar factor but caused severe contamination of the ICP-MS instrument by carbon. In the 3% v/v methanol solutions of arsenic and selenium the signal intensity from antimony (internal standard) was enhanced by a factor of 1.5, which indicates that the enhancement effect of the arsenic and selenium signals by methanol is only to a limited extent caused by improved sample transport/nebulization efficiency. It is proposed that an increased population of carbon ions or carbon-containing ions in the plasma facilitates a more complete ionization of analytes lower in ionization energy than carbon itself. The enhanced detection power for arsenic was applied to arsenic speciation by high-performance liquid chromatography (HPLC)–ICP-MS, and made possible the detection of the arsenocholine ion (AsC) in extracts of shrimp at the 5–10 ng g^–1 concentration level. The limit of detection was improved by a factor of 3.4 after addition of methanol and was 4.7 ng g^–1 as the AsC ion.

Background: Selenium is a potential chemopreventive agent against prostate cancer, whose chemoprotective effects are possibly mediated through the antioxidative properties of selenoenzymes. Interrelations with other antioxidative agents and oxidative stressors, such as smoking, are poorly understood. Objectives: The aims were to investigate the association between serum selenium and prostate cancer risk and to examine interactions with other antioxidants and tobacco use. Design: A nested case-control study was performed within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Serum selenium in prospectively collected samples was compared between 724 incident prostate cancer case subjects and 879 control subjects, frequency-matched for age, time since initial screen, and year of blood draw. The men were followed for up to 8 y. Results: Overall, serum selenium was not associated with prostate cancer risk (P for trend = 0.70); however, higher serum selenium was associated with lower risks in men reporting a high (more than the median: 28.0 IU/d) vitamin E intake [odds ratio (OR) for the highest compared with the lowest quartile of selenium: 0.58; 95% CI: 0.37, 0.91; P for trend = 0.05; P for interaction = 0.01] and in multivitamin users (OR for highest compared with the lowest quartile of selenium: 0.61; 95% CI: 0.36, 1.04; P for trend = 0.06; P for interaction = 0.05). Furthermore, among smokers, high serum selenium concentrations were related to reduced prostate cancer risk (OR for the highest compared with the lowest quartile of selenium: 0.65; 95% CI: 0.44, 0.97; P for trend = 0.09; P for interaction = 0.007). Conclusion: Greater prediagnostic serum selenium concentrations were not associated with prostate cancer risk in this large cohort, although greater concentrations were associated with reduced prostate cancer risks in men who reported a high intake of vitamin E, in multivitamin users, and in smokers.